Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01. 6 months of additional patient data since last update shows recurrence rate of less than1% per year in non-HLA-A*02 patients treated with GLSI-100. This less than1% Annual Recurrence Rate observed in non-HLA-A*02 Patients is statistically significantly sThan a 4% annual recurrence rate over a similar time period observed in the Katherine study yielding an spproximately 70-80% teduction in tecurrence tate as explained below. Final results may vary. Future updates may be presented at upcoming conferences. This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.